BioSapien Eyes Major Expansion Plans

BioSapien, the biotech firm behind the MediChip cancer treatment platform, has announced an extension to its pre‑Series A funding round, bringing total capital to more than $8 million. The company is adding a number of new hires across various departments.

The latest investor to join the round is Globivest, a women‑led, gender‑lens venture capital fund from the MENA region focused on life sciences. They join existing investors such as Global Ventures, Golden Gate Ventures, and Dara Holdings. The fund’s mission is to prove that financial returns and impact‑driven models can coexist, aligning with support for the World Health Organization’s ‘One Health’ approach.

New Investments and Team Members

BioSapien is also expanding its staff significantly, adding 12 new appointments. The new leadership includes Joseph Borrello PhD as Chief Technology Officer, Sonia Ramamoorthy MD MBA FACS as Head of Medical Affairs, and Agnes Westelinck PharmD as Head of Regulatory U.S. Also joining are Dirk Richter MD FACS as Head of Regulatory U.A.E., David Briere PhD as Director of Pharmacology, and Jerry Webb BSc as Head of Quality.

Beyond these roles, the firm is bringing on Zhiyu Xia PhD as Senior Manufacturing Engineer, Gaurav Vij MBA as Business Officer, and Nancy Sperling MS MS as the QC Lead. Rounding out the hires are Nivedita Sivakumar PharmD MS as Documentation and Compliance Manager, Manny Valenza BA as Clinical Development Associate, and Jared Rice BA as the Research and Operations Lead.

Company Growth and Development

Dr. Khatija Ali, CEO of BioSapien, said building a solid financial base and attracting skilled talent are essential for growing firms. She expressed satisfaction with the extended funding round and welcomed Globivest as a strategic partner, noting its unique position as a female‑led healthcare fund in the region.

Dr. Laura‑Joy Boulos, a partner at the fund, explained that the investment was driven by the search for companies offering truly transformative, science‑backed solutions. She described the MediChip platform as a breakthrough in localized cancer treatment, highlighting its scalability, precision, and alignment with the One Health mission.

These moves indicate BioSapien is strengthening both its financial standing and its team as it continues to develop its cancer treatment platform.